For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A091902

Trial Overview

Official Title

Testing The Addition Of Nivolumab To Chemotherapy In Treatment Of Soft Tissue Sarcoma

Study Purpose

To compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone.

Diagnosis

Patient has a type of cancer called angiosarcoma

Eligibility

Cutaneous or visceral angiosarcoma

Measurable disease

No prior PD-1, or VEGF TKI, PS 0-1

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: In Arm 1, participants will receive combination of paclitaxel and nivolumab. Participants assigned to Arm 2, will only receive paclitaxel.
  • Group 2: Patients who have been treated with "taxane" chemotherapy. In this group, participants will receive a combination of cabozantinib and nivolumab.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
A091902
Related Specialties